PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.

However, some patients with these adenocarcinomas tended to have higher levels of PI16 in the serum than healthy controls, but it did not reach statistical significance (Figure S2 ).

also in 111,027 other papers